This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Identifying a cSSTI patient who may benefit from Zinforo®

​​​​​​​In cSSTI patients, initial antimicrobial therapy failure is associated with 4-11 days longer in hospital and 4-12x higher mortality2-4

Laura, 71-year-old diabetic with cellulitis, presented with tender erythematous, non-raised lesions*

Severity:​​​​​​​
​​​​​​​
  • Deep and extensive cellulitis on the right leg that extends mid-calf to the ankle (~275 cm2)
  • Signs of systemic inflammatory response (Temp >38°C)
  • Rapid spread of erythema over past 24 hours
History/comorbidities:​​​​​​​
​​​​​​​
  • History of smoking
  • Type 2 insulin-dependent diabetes HbA1c= 7.4%
Risk factors for difficult-to-treat infection:​​​​​​​
​​​​​​​
  • ​​​​​​​Nursing home resident
  • Poorly managed diabetes

Martin, 44-year-old readmitted to hospital following inguinal hernia repair with purulent drainage from incision and localised pain*

Severity:

  • Signs of systemic inflammatory response (temp >38°C and heart rate >90 bpm)
History/comorbidities:​​​​​​​

  • ​​​​​​​History of depression (currently controlled by medication)
  • Obese (weight = 132 kg; BMI = 37)​​​​​​​
Risk factors for difficult-to-treat infection:
​​​​​​​
  • ​​​​​​​MRSA colonisation identified during admission screening for surgery

Mark, 67-year-old admitted to Accident and Emergency with a painful and fluctuant gluteal abscess*

Severity:​​​​​​​
​​​​​​​
  • Abscess area 12 cm2 with 95 cm2 surrounding cellulitis
  • Rapidly spreading infection
  • Signs of systemic inflammatory response (temp >38°C, heart rate >90 bpm, RR >20/min)
History/comorbidities:
​​​​​​​
  • ​​​​​​​Chronic renal impairment- CrCL at hospital admission = 17 mL/min
Risk factors for difficult-to-treat infection:​​​​​​​
​​​​​​​
  • Chronic renal disease
  • Treatment with fluoroquinolone within 6 months for UTI

When there's no time to wait, Zinforo provides swift, decisive action against cSSTIs†1,5,6

Learn about proven efficacy in cSSTI patients

Explore More

Read several CAP patient profiles describing potential scenarios where Zinforo could be a treatment of choice.

Access CAP patient profiles

To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study. 

View CAPTURE study data

*The examples described here are not actual patients, but fictitious representations of scenarios for which Zinforo could be considered.
†Refer to SmPC for further information on Zinforo.1

Abbreviations
​​​​​​​
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CANVAS, CeftAroliNe fosamil vs Vancomycin in Skin and skin structure infection; PORT, Pneumonia Patient Outcomes Research Team; MRSA, methicillin-resistant Staphylococcus aureus.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References
  1. ZINFORO. Summary of Product Characteristics
  2. Berger A, et al. Surg Infect 2013;14;304-12
  3. Edelsberg J, et al. Infect Control Hosp Epidemiol 2008;29:160-9
  4. Ostermann H, et al. J Med Econ 2013;17:719-29
  5. Corey G, et al. Clin Infect Dis 2010;51:641-50
  6. Friedland D, et al. Antimicrob Agents Chemother 2012;56:2231-6
  7. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  8. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  9. Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
PP-ZFO-GBR-0232. September 2021

Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials

View tolerability profile 

** This is an optional area where footnotes can live.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No